Canada markets closed

BELLUS Health Inc. (BLU.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
15.11+0.58 (+3.99%)
At close: 04:00PM EDT
Full screen
Previous Close14.53
Open14.87
Bid14.85 x 0
Ask15.25 x 0
Day's Range14.61 - 15.35
52 Week Range3.79 - 16.24
Volume115,950
Avg. Volume152,375
Market Cap1.901B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

    LAVAL, Quebec, August 10, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today reported its financial and operating results for the second quarter ending June 30, 2022.

  • Business Wire

    BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States

    LAVAL, Quebec, July 18, 2022--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the "Company" or "BELLUS Health") announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the "Offering") of 16,540,541 common shares at a price to the public of US$9.25 per common share. The total gross proceeds to the Company were US$153 million, before deducting the underwriting commissions and any expenses related to the Offering. Bellus has also gran

  • Business Wire

    BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

    LAVAL, Quebec, July 14, 2022--In connection with its previously announced public offering of common shares in Canada and the United States (the "Offering"), BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers and LifeSci Capital as lead manager (collectively, the "Underwriters"), relating to the public offering of 16,540,54